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Differences in bone turnover and intact PTH levels between
African American and Caucasian patients with end-stage renal
disease.
Background. Evidence derived from healthy subjects sug-
gests that African Americans have higher serum parathyroid
hormone (PTH) levels and decreased bone responsiveness to
PTH than Caucasians. African American patients with end-
stage renal disease (ESRD) also have higher serum PTH than
Caucasians. Studies that correlate intact PTH (iPTH) levels
with bone turnover in ESRD patients were performed in a
predominantly Caucasian population.
Methods. In this study, serum iPTH and bone histomorpho-
metric data were analyzed for racial differences in 76 ESRD
patients (Caucasian  48, African Americans  28). Bone
turnover was determined by histomorphometric measurement
of activation frequency in all patients.
Results. Age, duration of dialysis, and calcium and phospho-
rus levels were similar between the two groups. iPTH levels
(pg/mL; mean  SE) were significantly higher in the African
American group (534  79 vs. 270  46, P  0.01). Also,
alkaline phosphatase levels (IU/L) were significantly higher in
the African American group (162 31 vs. 144 43, P 0.01).
Correlations between PTH levels and activation frequency
were r  0.60, P  0.01 in Caucasians and r  0.22, P 
NS in African Americans. The mean PTH level in African
American patients with histologic findings of low bone turnover
was 460  115 vs. 168  41 in Caucasian patients with similar
bone turnover (P  0.01). In patients with low bone turnover,
African Americans had significantly higher osteoid volume
and thickness, number of osteoblasts and osteoclasts, erosion
surface, peritrabecular fibrosis, and single-label surface than
Caucasians. However, erosion depth, bone formation rate per
osteoblast and mineralization apposition rate were similar be-
tween the two groups.
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Conclusion. There is no correlation between iPTH and bone
turnover in African Americans with ESRD. A substantial num-
ber of African American patients with low bone turnover have
very high serum PTH levels. Bone histomorphometric results
reveal differences in remodeling dynamics and responses to
PTH between African American and Caucasian patients. Fur-
ther studies utilizing newer PTH measurement assays are
needed to better delineate the correlation between PTH and
bone turnover in the various racial groups.
African Americans with normal kidney function have
higher parathyroid hormone (PTH) serum levels and
larger parathyroid glands than Caucasians [1–7]. They
also have higher bone mineral density [7, 8] and lower
serum osteocalcin levels [1, 2, 6], findings that are sugges-
tive of lower bone turnover. Weinstein and Bell [9] have
demonstrated, by histomorphometric analysis, that nor-
mal African American subjects have a lower bone forma-
tion rate than Caucasians. Cosman et al [10] have shown
that the bone response to PTH (1-34) infusion, assessed
by measuring bone resorption markers (pyridinoline,
N-telopeptide, C-telopeptide), is less in African Ameri-
cans than Caucasian women.
We have recently reported that African American pa-
tients with end-stage renal disease (ESRD) have higher
serum PTH levels than Caucasian patients at the time of
dialysis initiation [11]. This was also observed in cross-
sectional studies of patients on maintenance dialysis
[12, 13]. However, whether the higher serum levels of
PTH in African American patients are also associated
with more severe hyperparathyroid bone disease has not
been established. Potential differences are important to
consider when defining target PTH levels in ESRD pa-
tients, since oversuppression of parathyroid glands can
lead to adynamic bone disease [14].
The purposes of this study were (1) to evaluate the
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relationship between intact PTH (iPTH) levels and bone
turnover in African Americans and Caucasian ESRD
patients on maintenance dialysis, and (2) to compare
iPTH levels and bone histomorphometric parameters
between the two races in patients with similar bone turn-
over rate.
METHODS
Subjects
Patients who underwent bone biopsy between 1992
and 2000 were evaluated for this study. All patients were
from Central and Southeastern Kentucky. They were all
managed in the same dialysis units from which the sub-
jects were chosen. The following patients were excluded:
(1) patients followed by nephrologists other than the
University of Kentucky group, patients with incomplete
relevant clinical or biochemical data, or those with in-
complete tetracycline labeling of bone; (2) patients who
had a history of renal transplant or parathyroidectomy;
and (3) patients with positive aluminum stain on bone
biopsy. Patients with aluminum accumulation and those
who had renal transplant or underwent parathyroidec-
tomy were excluded since in these patients the relation-
ship between PTH levels and bone turnover is variable
and not systematically defined. From a total of 170 pa-
tients in whom complete bone histomorphometric data
were available, 76 met the above criteria. Forty-eight pa-
tients were Caucasians (63%) and 28 were African Ameri-
cans (37%). The percent of African American patients
in this study is very similar to that of the total pool
of dialysis patients from which the study population is
derived (African Americans 30%). Fifty-four bone bi-
opsies (71%) were performed as baseline biopsies in
various prospective clinical studies. Twenty-two biopsies
(29%) were performed for diagnostic purposes.
Biochemical analysis
Total serum calcium, phosphorus, and alkaline phos-
phatase levels were measured by standard techniques.
All blood samples were obtained within 3 weeks of the
bone biopsy. On the day of biopsy, concentrations of se-
rum iPTH were determined in duplicate by the two-site
immunoradiometric assay (IRMA) for iPTH using the
Allegro iPTH Assay Kit (Nichols Institute, San Juan Capi-
strano, CA, USA). Normal values were 15 to 65 pg/mL;
intra- and interassay coefficients of variations were 4%
and 7%, respectively.)
Bone biopsy, mineralized bone histology, and
bone histomorphometry
Twenty days before bone biopsy, patients received
tetracycline hydrochloride for bone labeling at a dose of
500 mg orally twice a day for 2 days. No tetracycline
antibiotic was administered for the following 10 to 14
days. A second label of oral tetracycline hydrochloride
(500 mg twice a day) or demeclocycline hydrochloride
(Declomycin; Lederle, Wayne, NJ, USA) (300 mg twice
a day) was administered for the next 4 days. Phosphate
binders and other antacids were not given on days of
tetracycline administration. All patients underwent bone
biopsy 3 to 4 days after receiving the second label. Bone
samples were taken from the anterior iliac crest with an
electric drill (Straumann Medical, Waldenburg, Switzer-
land; or MDTECH, Inc., Gainesville, FL, USA). Bone
samples were processed as previously described [15].
Sections were stained with the modified Masson-Gold-
ner trichrome stain [16]. The aurin tricarboxylic acid
stain [17] was used to measure the extent of aluminum
deposits at the bone-osteoid interface, and solochrome
azurine [18] was used as control and for detection of
aluminum within bony trabeculae. Unstained sections
were prepared for phase contrast and fluorescent light
microscopy.
Histomorphometric parameters were measured using
the Osteoplan System II (Kronton, Munich, Germany)
as previously described [19, 20]. Activation frequency
represents the inverse of total remodeling period, which
includes formation, reversal, resorption, and quiescent
periods and is the histomorphometric parameter of bone
turnover [21]. Activation frequency in normal control
subjects studied in our laboratory is 0.65  0.04 year1.
Statistical analysis
Results are expressed as mean values  SEM. All
statistical tests were two-sided and an assigned signifi-
cance level of 0.05 was used. Differences between numer-
ical variables were tested using the nonparametric Mann-
Whitney U test. Differences in categoric variables were
checked with the chi-square tests. Pearson’s coefficients
of correlation were obtained between activation fre-
quency and serum PTH levels. All computations were
performed using the SPSS software for Windows, version
7.5.1 (SPSS, Chicago, IL, USA).
RESULTS
There was no difference in age, gender, diabetes status,
duration of dialysis, or the use of vitamin D therapy be-
tween the African American and Caucasian groups (Ta-
ble 1). There were more Caucasian patients on peritoneal
dialysis than African American patients. However, simi-
lar results were obtained when only hemodialysis pa-
tients were compared between the two racial groups.
Therefore, the combined results of both hemodialysis
and peritoneal dialysis patients were reported. African
American patients had higher serum levels of iPTH,
despite similar serum phosphorus and calcium concen-
trations (Table 2). Alkaline phosphatase was also higher
in the African American group (Table 2).
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Table 1. Patients’ characteristics and demographic data
Caucasians (C) African Americans (AA) P value
(N  48) (N  28) (C vs. AA)
Age years 47.72.2 482.6 NS
Male/female % 62/38 46/54 NS
Diabetics % 31 18 NS
Hemodialysis/peritoneal dialysis % 56/44 86/14 0.01
Duration of dialysis months 20.13.0 13.62.9 NS
Vitamin D therapy % 20 23 NS
Table 2. Intact parathyroid hormone (PTH) and biochemical profile
Caucasians (C) African-Americans (AA) P value
(N  48) (N  28) (C vs. AA)
PTH
(15–65 pg/mL) 27046 53479 0.01
Calcium
(8.4–10.2 mg/dL) 9.60.2 9.10.2 NS
Phosphorus
(2.7–4.5 mg/dL) 6.40.3 6.20.4 NS
Alkaline phosphatase
(20–70 U/L) 14443 16231 0.01
In Caucasian patients, there was a positive correlation
between serum iPTH levels and activation frequency
(Fig. 1A) (r  0.60, P  0.01). However, no correlation
between these two parameters was demonstrated in Afri-
can American patients (Fig. 1B) (r  0.22, P  NS).
Similar results were obtained when patients receiving
vitamin D were excluded from the analysis. PTH levels
in Caucasian patients with low bone turnover were sig-
nificantly lower than in Caucasian patients with high
bone turnover (Fig. 2). However, in African American
patients, no differences in PTH levels were found be-
tween the two groups. The mean PTH level of African
American patients with low bone turnover was 460 
115 pg/mL, which is significantly higher than that of
Caucasian patients with similar bone turnover (168 
41 pg/mL; P  0.01).
A comparison of the histomorphometric parameters
of African American and Caucasian patients with low
bone turnover revealed that African American patients
had significantly higher osteoid volume and thickness,
number of osteoblasts and osteoclasts, erosion surface,
peritrabecular fibrosis, and single-label surface (Table 3).
Erosion depth, bone formation rate per osteoblast, and
mineralization apposition rate were similar in the two
groups (Table 3). Histomorphometric parameters of pa-
tients with high bone turnover were similar in both racial
groups, except osteoid thickness was significantly higher
in African American patients (data not shown).
DISCUSSION
For more than a decade, the two-site IRMA for serum
iPTH levels has been used in dialysis patients to evaluate
secondary hyperparathyroidism and to indicate the need
for vitamin D therapy. Assays that measure iPTH were
more reliable than those directed to the C-terminal or
midregion of the PTH molecule [22]. We and others
have recently reported that African American patients
with ESRD have significantly higher serum iPTH levels
than Caucasians [11, 12]. Whether the target PTH level
in ESRD patients should be different across racial groups
is unknown [11, 23]. Recent studies describing serum
iPTH levels and bone histology in ESRD patients have
been performed, predominantly in Caucasian popula-
tions [22, 24–28]. There is sufficient evidence in normal
subjects to suggest that African Americans may require
higher PTH levels to maintain a bone turnover rate simi-
lar to Caucasians.
The results of this study confirm that African Ameri-
can patients with ESRD have higher serum PTH levels
than Caucasians. A significant positive correlation be-
tween PTH and bone turnover is found only in Caucasian
patients. The correlation coefficient for iPTH and bone
turnover in this racial group is similar to what was pre-
viously reported [24, 26, 28]. However, there is no corre-
lation between PTH and bone turnover in African Amer-
ican patients.
In patients with low bone turnover, the presence of
significantly higher iPTH levels in African Americans,
as compared to Caucasians, indicates that many African
American patients have either end-organ resistance to
the bone effect of PTH or the iPTH measurement in
these patients cross reacts with inert PTH fragments. It
has been recently reported that the commercially avail-
able kits for determinations of iPTH also measure a large
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Fig. 1. Correlation between intact parathyroid hormone and activation
frequency in (A) Caucasians (r  0.60, P  0.01), and (B) African
Americans (r  0.22, P  NS).
C-terminal fragment (7-84 amino acid) that may have
antagonistic effects on the intact 1-84 amino acid mole-
cule [29, 30]. It remains to be determined whether Afri-
can American patients have higher circulating levels of
these antagonistic C-terminal fragments.
Skeletal resistance to the hypercalcemic effects of PTH
in uremic patients was observed decades ago [31–33].
However, resistance of uremic bone to the remodeling
effects of PTH is not well documented. Evidence for such
resistance is presumed on the basis that ESRD patients
require higher serum PTH levels to maintain normal
bone turnover [24, 26–28]. Since, in these studies, PTH
was measured by the commercially available IRMAs,
the role of PTH fragments in those results is not clear.
In studies that measured the true iPTH (1-84), a number
of patients still exhibited low bone turnover in the face
of normal or even high iPTH levels [22, 30]. However,
this finding may be explained by the presence of an
imbalance between the ratio of 1-84 PTH and antagonis-
tic PTH fragments [30]. This difference in bone remodel-
ing effects of PTH between African American and Cau-
casian ESRD patients has not been previously addressed.
The observation that African American patients with
Fig. 2. Intact parathyroid hormone (PTH) in African-Americans (AA)
and Caucasians (C) with low and high bone turnover (BT). *P  0.01
compared to PTH levels in all other groups.
low bone turnover have higher osteoid volume and thick-
ness, number of osteoblasts and osteoclasts, erosion sur-
face, and peritrabecular fibrosis than Caucasian patients
with low bone turnover is consistent with African Ameri-
can patients having higher PTH activity on bone. How-
ever, erosion depth, bone formation rate per osteoblast,
and mineralization apposition rate, which are parameters
of cellular activity, were not different between these two
groups. These results suggest differences in remodeling
dynamics between African American and Caucasian pa-
tients. The finding of higher single-label surface in the
African American group corroborates this notion. The
mechanism of this difference in bone remodeling activity
remains speculative at this time.
The effect of PTH is mediated through the PTH/
PTHrP receptor. Results regarding the status of this re-
ceptor in uremic patients are contradictory [34, 35]. Ra-
cial differences in the bone concentration of this receptor
have not been assessed. It is conceivable that African
American patients have lower receptor concentration
that may explain at least part of the observed results.
Vitamin D is a known modulator of PTH action
[33, 36]. A traditional interpretation of the skeletal resis-
tance to PTH in healthy African Americans is attributed
to an adaptive mechanism to compensate for the com-
monly seen relative 25-hydroxy vitamin D deficiency in
African Americans [37, 38]. However, Cosman et al [10]
have demonstrated that the role of 25-hydroxy vitamin
D in this apparent PTH resistance is minor at most. In
our study, there was no difference in the use of vitamin
D metabolites between the two racial groups, and similar
results were obtained when patients receiving vitamin
D were excluded from the analysis. However, we have
not assessed vitamin D levels in these patients.
Racial differences in vitamin D receptor gene poly-
morphism have been reported in some studies [39], but
not in all [40]. Whether vitamin D receptor polymor-
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Table 3. Static and dynamic histomorphometric parameters in patients with low bone turnover
Caucasians (C) African Americans (AA) Normal P value
(N  31) (N  15) valuesa (C vs. AA)
Bone volume/tissue volume % 21.41.8 21.12.5 16.8–22.9 NS
Osteoid volume/tissue volume % 5.01.3 8.92.3 0.57–6.0 0.02
Osteoid surface/bone surface % 32.73.9 41.85.0 3.45–37.9 NS
Osteoid thickness lm 7.21.2 9.81.2 4.38–11.8 0.01
Osteoblast number/bone length
(per 100 mm) 5210 266110 10–240 0.01
Erosion surface/bone surface % 3.60.6 7.41.2 1–5.7 0.01
Erosion depth lm 10.91.0 13.61.6 1.63–11.2 NS
Osteoclast number/bone length
(per 100 mm) 3910 559 0.01–36.1 0.05
Fibrosis surface/bone surface % 0.40.2 6.53.7 0 0.01
Mineralization apposition rate
lm/day 0.680.07 0.510.05 0.43–0.63 NS
Single-label surface/bone
surface % 2.60.6 6.01.5 0.29–26.4 0.01
Bone formation rate/tissue
volume mm3/cm3/year 27.413 37.619.8 11.5–110 NS
Bone formation rate/osteoblast
number mm2/ob/year 3211 104.0 N/A NS
Activation frequency (year-1) 0.190.03 0.220.05 0.49–0.72 NS
N/A is not available.
a Available in Caucasian subjects only
phism plays a role in the histologic differences between
African American and Caucasian ESRD patients re-
mains to be examined. Finally, it is currently recognized
that numerous local factors and cytokines affect bone
remodeling [41, 42]. Possible racial differences among
these factors await further research.
Limitations of this study include potential patient se-
lection bias. This would have been particularly important
if the objective of the study was to evaluate the preva-
lence of the various renal osteodystrophy histologic pat-
terns in the two racial groups. However, in this study
we are attempting to evaluate the relationship between
iPTH and bone turnover in a given racial group. Also,
the number of patients on peritoneal dialysis is too small
to allow analysis of the effect of this modality on the
observed racial differences in bone remodeling.
CONCLUSION
This study demonstrates that iPTH levels in African
American patients with ESRD do not correlate with bone
turnover as they do in Caucasian patients. Many African
American patients with low bone turnover have substan-
tially high iPTH levels. These findings have an impact
on current clinical practice in defining the target iPTH
level in ESRD patients.
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